Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Reliq Health Technologies Inc V.RHT.H

Alternate Symbol(s):  RQHTF

Reliq Health Technologies Inc. is a global healthcare technology company that specializes in developing virtual care solutions for the healthcare market. The Company’s iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive care at home, improving health outcomes, enhancing quality of life for patients and families and... see more

TSXV:RHT.H - Post Discussion

View:
Post by aaaaaargh on Jan 06, 2023 9:46am

News

I am most interested in the corporate update on the 11 th, so we can hopefully get new guidance.   Then we can take 10-20% of said guidance to have an idea of where we are actually headed for this upcoming year.   Unless of course,  someones  new years resolution was to finally under promise and over deliver for once.   

Fingers are crossed for an update with real financials, and not more hopium and meaningless word salad.
Comment by lscfa on Jan 06, 2023 11:08am
No consistency in NR's.... co. should announce the expected annual recurring revenue from these contracts rather than leave it to readers to interpret and calculate confusing no.s. Jan 6 - We expect to add approximately 1,700 patients per month to our platform from these clients, or over 20,000 patients per year with revenues of $65 per patient per month at 75% gross margin.” Dec 6 -& ...more  
Comment by Lifeboat1 on Jan 06, 2023 11:33am
Iscfa - If a news release is unclear to you, ask IR for clarification and then enlighten us all instead of just complaining about everything.  Didn't anyone ever tell you to brimgnsolutions not just complaints.
Comment by qwerty22 on Jan 06, 2023 11:31am
Funny. What I'd love is a graph with monthly revenue for 2022 up to the end of Dec so we could maybe make sense of the two steps forward two steps back scenario that seems to have played out . Forget the future I'm still trying to make sense of the past. I guess that might be too revealing. (Maybe she can include some of the best future hurricane season prediction as well ...more  
Comment by Lifeboat1 on Jan 06, 2023 11:39am
Query22 - Quarterly revenue has only been 2 steps forward for 18 months.  There have been no steps back.  The data is available to the end of September. if you had any business sense you would know that there is always monthly variations which is why Companies generally only report quarterly to smooth out those variations to give investors a more accurate picture of progress ...more  
Comment by qwerty22 on Jan 06, 2023 12:10pm
You mean like Lisa who speculates/claims revenue was hit by Covid and hurricanes? Who speculates, I mean issues guidance, that revenue will be through the roof and it's far from that. If she can see that in the data I'd like to see it. If she's just speculating I'd like to know that. I'd like to know the business model is firing on all cylinders but they got unlucky. I suspect ...more  
Comment by lscfa on Jan 06, 2023 12:17pm
You can see the COVID hit in Jun qtr sass....   Qtr ending Sep 22 Jun 22 Mar 22 Dec 21 Sept 21 SAAS rev 1,422,671 783,659 1,067,426 524,547 363,884  ...more  
Comment by Lifeboat1 on Jan 06, 2023 12:17pm
The revenue Guidance and trajectory has been right on target but with 6 months to a year delay.  Not unusual for a growing business in a new market.  They hit the 1.5 million of quarterly revenue, they will likely hit > 11 million in revenue in calendar 2022 and I suspect they will hit $40 million in revenue for calendar 2023.  For a long they are hitting all the milestones just ...more  
Comment by EdinColorado on Jan 06, 2023 12:55pm
I like your summary. For the past couple few years I have bought with the intention of investing in the process that seems to be leading us steadily toward the product of revenue. The fact that we have not yet generated the product of revenue is what keeps this stock speculative, high risk and volatile--a "portfolio destroyer" at times. However, after the product has been generated ...more  
Comment by qwerty22 on Jan 06, 2023 1:17pm
Trajectory? You see the long promised trajectory in the Q numbers for SaaS? It's SaaS that matters and there is no positive trajectory atm. It's not there and the excuses why it isn't there are weak. If those excuses are real I'm pretty sure they could be better revealed by a deeper dive into the revenue numbers. She doesn't need to do that caused people like you already ...more  
Comment by Lifeboat1 on Jan 06, 2023 1:47pm
I do.  SAAS was up somewhere in the range of 3,000% yoy.  That's a nice trajectory.  Devices are part of the current business model and are a differentiator and have good margin.  Most Companies would love to have their main business with GM at 50% while Reliq has that for a pass through product.  The Company will have higher valuation with devices  than without ...more  
Comment by qwerty22 on Jan 06, 2023 4:14pm
Whether your 3000% is right or not doesn't matter. It as much tells you they started from a tragically low place as where they ended. We all know they had two false starts, I guess you are just forgiving them that and discounting it happening again. Let's look at absolute revenue growth. Dec21 to Mar22 Q SaaS revenue grew $500,000 Mar22 to Sept22 (forgiving the Covid Q) Quarterly SaaS ...more  
Comment by lscfa on Jan 06, 2023 12:00pm
The way these NRs are worded is just another way co. is overpromising.       Announced Patients Monthy rate Annual Revenue 2023 Jan 6 20,000 65 15,600,000 2022  ...more  
Comment by lscfa on Jan 06, 2023 3:23pm
Assuming 100% of these patients will take this service is ridiculous. Original Medicare patients have to pay 20% of the monthly fee for each service and many will not consent. If clinician is providing more than 1 virtual care service (e.g. CCM , RPM, etc) patient has to pay $7-$10 per month for each.   Chronic Care Management: Patient Cost vs. Value While chronic care management is ...more  
Comment by Lifeboat1 on Jan 06, 2023 3:49pm
Iscfa - This is getting tiresome.  Would you actually do one DD.  No where did Reliq say it was 100% of patients.  When asked in the past IR has said the number they quote is after applying the amount that are eligible and likely to consent to the program.  Collection of copays are waived in the US during the health emergency which lasts through 2023.  Most Medicare ...more  
Comment by Lifeboat1 on Jan 06, 2023 3:53pm
Iscfa - You actually posted all the data that supports what I said in my post.  Even when you post the right information you somehow come to the wrong conclusion.
Comment by lscfa on Jan 06, 2023 3:57pm
reread the material I provided, dumbass. Less than 50% of Medicare patients have Medicare Advantage. 
Comment by lscfa on Jan 06, 2023 4:11pm
As these clients are part of "a previously disclosed contract" there is no value added. Stock price should not react.
Comment by Stocker46 on Jan 06, 2023 10:15pm
Read the NR Iscfa, it states "added 34 new". Your posts are becoming somewhat asinine!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities